Cargando…

Immune dysregulation in Glycogen Storage Disease 1b - a CyTOF approach

Glycogen Storage Disease type 1b (GSD1b) is a rare disease manifesting as hypoglycemia, recurrent infections and neutropenia, resulting from deleterious mutations in the SLC37A4 gene encoding the glucose-6-phosphate transporter. The susceptibility to infections is thought to be attributed not only t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gehlhaar, Arne, Shouval, Dror, Santiago, Eduardo Gonzalez, Ling, Galina, McCourt, Blake, Werner, Lael, Yerushalmi, Baruch, Konnikova, Liza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980199/
https://www.ncbi.nlm.nih.gov/pubmed/36865166
http://dx.doi.org/10.21203/rs.3.rs-2598829/v1
_version_ 1784899867010662400
author Gehlhaar, Arne
Shouval, Dror
Santiago, Eduardo Gonzalez
Ling, Galina
McCourt, Blake
Werner, Lael
Yerushalmi, Baruch
Konnikova, Liza
author_facet Gehlhaar, Arne
Shouval, Dror
Santiago, Eduardo Gonzalez
Ling, Galina
McCourt, Blake
Werner, Lael
Yerushalmi, Baruch
Konnikova, Liza
author_sort Gehlhaar, Arne
collection PubMed
description Glycogen Storage Disease type 1b (GSD1b) is a rare disease manifesting as hypoglycemia, recurrent infections and neutropenia, resulting from deleterious mutations in the SLC37A4 gene encoding the glucose-6-phosphate transporter. The susceptibility to infections is thought to be attributed not only to the neutrophil defect, though extensive immunophenotyping characterization is currently missing. Here we apply a systems immunology approach utilizing Cytometry by Time Of Flight (CyTOF) to map the peripheral immune landscape of 6 GSD1b patients. When compared to control subjects, those with GSD1b had a significant reduction in anti-inflammatory macrophages, CD16(+) macrophages, and Natural Killer cells. Additionally, there was a preference towards a central versus an effector memory phenotype in multiple T cell populations, which may suggest that these changes stem from an inability of activated immune cell populations to undergo the appropriate switch to glycolytic metabolism in the hypoglycemic conditions associated with GSD1b. Furthermore, we identified a global reduction of CD123, CD14, CCR4, CD24 and CD11b across several populations and a multi-cluster upregulation of CXCR3, hinting at a potential role of impaired immune cell trafficking in the context of GSD1b. Taken together, our data indicates that that the immune impairment observed in GSD1b patients extends far beyond neutropenia and encompasses innate and adaptive compartments, which may provide novel insights into the pathogenesis of this disorder.
format Online
Article
Text
id pubmed-9980199
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Journal Experts
record_format MEDLINE/PubMed
spelling pubmed-99801992023-03-03 Immune dysregulation in Glycogen Storage Disease 1b - a CyTOF approach Gehlhaar, Arne Shouval, Dror Santiago, Eduardo Gonzalez Ling, Galina McCourt, Blake Werner, Lael Yerushalmi, Baruch Konnikova, Liza Res Sq Article Glycogen Storage Disease type 1b (GSD1b) is a rare disease manifesting as hypoglycemia, recurrent infections and neutropenia, resulting from deleterious mutations in the SLC37A4 gene encoding the glucose-6-phosphate transporter. The susceptibility to infections is thought to be attributed not only to the neutrophil defect, though extensive immunophenotyping characterization is currently missing. Here we apply a systems immunology approach utilizing Cytometry by Time Of Flight (CyTOF) to map the peripheral immune landscape of 6 GSD1b patients. When compared to control subjects, those with GSD1b had a significant reduction in anti-inflammatory macrophages, CD16(+) macrophages, and Natural Killer cells. Additionally, there was a preference towards a central versus an effector memory phenotype in multiple T cell populations, which may suggest that these changes stem from an inability of activated immune cell populations to undergo the appropriate switch to glycolytic metabolism in the hypoglycemic conditions associated with GSD1b. Furthermore, we identified a global reduction of CD123, CD14, CCR4, CD24 and CD11b across several populations and a multi-cluster upregulation of CXCR3, hinting at a potential role of impaired immune cell trafficking in the context of GSD1b. Taken together, our data indicates that that the immune impairment observed in GSD1b patients extends far beyond neutropenia and encompasses innate and adaptive compartments, which may provide novel insights into the pathogenesis of this disorder. American Journal Experts 2023-02-23 /pmc/articles/PMC9980199/ /pubmed/36865166 http://dx.doi.org/10.21203/rs.3.rs-2598829/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. https://creativecommons.org/licenses/by/4.0/License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Article
Gehlhaar, Arne
Shouval, Dror
Santiago, Eduardo Gonzalez
Ling, Galina
McCourt, Blake
Werner, Lael
Yerushalmi, Baruch
Konnikova, Liza
Immune dysregulation in Glycogen Storage Disease 1b - a CyTOF approach
title Immune dysregulation in Glycogen Storage Disease 1b - a CyTOF approach
title_full Immune dysregulation in Glycogen Storage Disease 1b - a CyTOF approach
title_fullStr Immune dysregulation in Glycogen Storage Disease 1b - a CyTOF approach
title_full_unstemmed Immune dysregulation in Glycogen Storage Disease 1b - a CyTOF approach
title_short Immune dysregulation in Glycogen Storage Disease 1b - a CyTOF approach
title_sort immune dysregulation in glycogen storage disease 1b - a cytof approach
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980199/
https://www.ncbi.nlm.nih.gov/pubmed/36865166
http://dx.doi.org/10.21203/rs.3.rs-2598829/v1
work_keys_str_mv AT gehlhaararne immunedysregulationinglycogenstoragedisease1bacytofapproach
AT shouvaldror immunedysregulationinglycogenstoragedisease1bacytofapproach
AT santiagoeduardogonzalez immunedysregulationinglycogenstoragedisease1bacytofapproach
AT linggalina immunedysregulationinglycogenstoragedisease1bacytofapproach
AT mccourtblake immunedysregulationinglycogenstoragedisease1bacytofapproach
AT wernerlael immunedysregulationinglycogenstoragedisease1bacytofapproach
AT yerushalmibaruch immunedysregulationinglycogenstoragedisease1bacytofapproach
AT konnikovaliza immunedysregulationinglycogenstoragedisease1bacytofapproach